Sleep drug could quiet breathing pauses in apnea

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria Individuals are eligible for participation in this study if they have all of the followings: 1. Patient, aged 18 - 65 years at the time of informed consent 2. Voluntary agreement and capable for giving written informed consent 3. Diagnosis with OSA according to the criteria of the International Classification of Sleep Disorders, version 3 Text Revision 4. Baseline screening polysomnography (PSG) demonstrated apnea-hypopnea index 15 - 30 events/h of sleep (moderate severity) 5. Patients identified as low arousal threshold using previously recommended criteria which allocated a score of 1 to each criterion: apnea-hypopnea index \< 30 events per hour, nadir oxygen saturation as measured by pulse oximetry \> 82.5%, and fraction of hypopneas \> 58.3%. A score of 2 or above defined a low arousal threshold. 6. Peripheral capillary oxygen saturation (SpO2) ≥ 94% measured during screening visit 7. Habitually sleeping ≥ 5.5 hours/night with usual bedtime falls within the range of 9:00 PM to 1:00 AM 8. Body mass index 18 - 40 kg/m2 Exclusion criteria Individuals were not eligible for participation in this study if they have any of the followings: 1. Previous allergy or adverse effects with Lemborexant or other sedatives 2. Pregnant or breastfeeding 3. Significant medical comorbidities that could affect individual safety and study assessment results, regarding investigators' opinion 4. Uncontrolled cardiovascular or cerebrovascular diseases 5. Neuromuscular diseases 6. Nasal anatomical defect 7. Significant psychiatric comorbidities that could affect individual safety and study assessment results, regarding investigators' opinion 8. Active respiratory disorders other than OSA 9. Central respiratory events (CAHI) \>25% of the total AHI 10. Diagnosis/symptoms of sleep-related disease other than OSA including narcolepsy, restless legs syndrome, periodic limb movement disorder, or circadian rhythm sleep-wake disorder 11. Severe hypersomnolence (ESS ≥16) 12. Peripheral capillary oxygen saturation (SpO2) \< 80% for ≥ 5% of total sleep time measured during screening visit 13. Driving-related sleepiness accident or near misses in the past 12 months 14. Safety-critical occupation 15. Using CPAP or other dental devices within 2 weeks of screening polysomnography until the end of the study 16. Unable to tolerate equipment in this study 17. Taking any medication that affects sleep or other variable measured in this study 18. Taking any medication with cytochrome P450 Family 3A (CYP3A) inhibitors and all CYP3A inducers 19. Drug or alcohol use disorder within 2 years before the study initiation or current excessive alcohol intake 20. Excessive caffeine intake